Targeted therapies for renal cell carcinoma: understanding their impact on survival (Q37772813)

22 August 2017

1 reference

title

Targeted therapies for renal cell carcinoma: understanding their impact on survival (English)

1 reference

22 August 2017

1 reference

Sumanta Kumar Pal

1

1 reference

PubMed ID

20632214

22 August 2017

Robert A Figlin

series ordinal

2

1 reference

22 August 2017

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

5

1 reference

22 August 2017

2

1 reference

22 August 2017

131-138

1 reference

https://scigraph.springernature.com/pub.10.1007/s11523-010-0145-6

22 August 2017

0 references

cites work

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11523-010-0145-6

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

21 January 2018

1 reference

12 December 2020

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

12 December 2020

Lessons learned from independent central review

1 reference

12 December 2020

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

12 December 2020

More clinical cancer treatments judged by progression-free rather than overall survival

1 reference

12 December 2020

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

12 December 2020

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

12 December 2020

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

1 reference

12 December 2020

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

12 December 2020

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 reference

12 December 2020

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

12 December 2020

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

12 December 2020

Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel

1 reference

12 December 2020

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

1 reference

12 December 2020

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

12 December 2020

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging

1 reference

12 December 2020

Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set

1 reference

12 December 2020

Immunotherapy of renal cell carcinoma

1 reference

12 December 2020

1 reference

12 December 2020

Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma

1 reference

12 December 2020

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

12 December 2020

10.1007/S11523-010-0145-6

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20632214